novartis ag zelmac pulled by swiss for heart stroke risks switzerlands pharmaceuticals regulator said it ordered novartis ag to pull its bowel drug zelmac from the market saying its risks outweighed its benefits swissmedic said a new analysis of data from clinical studies revealed an increased risk of angina heart attacks and strokes when compared with a placebo novartis based in switzerland said it is complying with the order but remains convinced that zelmac has important benefits for certain patients novartis agreed in march to stop selling the drug also known as zelnorm in the u s after it was linked to a higher chance of heart attacks and strokes 
